Qutenza FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved November 16, 2009)
Brand name: Qutenza
Generic name: capsaicin
Dosage form: Transdermal Patch
Company: Averitas Pharma, Inc.
Treatment for: Neuropathic Pain, Postherpetic Neuralgia, Diabetic Peripheral Neuropathy
Qutenza (capsaicin) is a TRPV1 channel agonist indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet.
- Capsaicin contained in Qutenza can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin. Qutenza must be administered only by a healthcare provider.
- Qutenza patches are applied for 60 minutes for the treatment of PHN, and 30 minutes for DPN of the feet. Treatment can be repeated no more frequently than every three months.
- Common adverse reactions include application site erythema, application site pain, and application site pruritus.
Development timeline for Qutenza
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
